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Accepted 15 May 2017; Published online 20 May 2017AbstractObjective: To identify the occurrence and determinants of protocol-publication discrepancies in clinical drug trials.
Study Design and Setting: All published clinical drug trials reviewed by the Dutch institutional review boards in 2007 were analyzed.
Discrepancies between trial protocols and publications were measured among key reporting aspects. We evaluated the association of trial
characteristics with discrepancies in primary endpoints by calculating the risk ratio (RR) and 95% confidence interval (CI).
Results: Of the 334 published trials, 32 (9.6%) had a protocol/publication discrepancy in the primary endpoints. Among the subgroup
of randomized controlled trials (RCTs; N5 204), 12 (5.9%) had a discrepancy in the primary endpoint. Investigator-initiated trials with and
without industry (co-) funding were associated with having discrepancies in the primary endpoints compared with industry-sponsored trials
(RR 3.7; 95% CI 1.4e9.9 and RR 4.4; 95% CI 2.0e9.5, respectively). Furthermore, other than phase 1e4 trials (vs. phase 1; RR 4.6; 95%
CI 1.1e19.3), multicenter trials were also conducted outside the European Union (vs. single center; RR 0.2; 95% CI 0.1e0.6), not pro-
spectively registered trials (RR 3.3; 95% CI 1.5e7.5), non-RCTs (vs. superiority RCT; RR 2.4; 95% CI 1.2e4.8) and, among the RCTs,
crossover compared with a parallel group design (RR 3.7; 95% CI 1.1e12.3) were significantly associated with having discrepancies in the
primary endpoints.
Conclusions: Improvement in completeness of reporting is still needed, especially among investigator-initiated trials and non-RCTs. To
eliminate undisclosed discrepancies, trial protocols should be available in the public domain at the same time when the trial is
published.  2017 Elsevier Inc. All rights reserved.
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Selective reporting is considered to be the most impor-
tant cause of the poor reproducibility of biomedical
research [1]. If mainly the positive results of a study are
published, this may lead to overrepresentation of positive
results and conclusions in the scientific literature [2].Conflict of interest: None.
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E-mail address: p.c.souverein@uu.nl (P.C. Souverein).
http://dx.doi.org/10.1016/j.jclinepi.2017.05.012
0895-4356/ 2017 Elsevier Inc. All rights reserved.Ignoring negative results can cause research waste, as futile
experiments may be unnecessarily repeated [3]. Moreover,
an inadequate description of the protocol of a study can
frustrate replication of the study [4,5]. Transparency of
the process from study protocols until publication remains
therefore paramount in the responsible conduct of research.
Complete and unbiased publication of clinical trials is an
ethical and scientific obligation as recommendations and
conclusions derived from clinical trials are often translated
into clinical guidelines, and human participants were
involved in obtaining the results [6].
One type of selective reporting is nonpublication [7].
Evidence across medical and geographical areas shows that
approximately half of the clinical trials that are conducted
Inception cohort: clinical drug trials reviewed by
Dutch IRBs in 2007:
N = 622
Approved by Dutch IRBs:
N = 603
Trial is still ongoing: N = 10
Never started inclusion of patients: N = 19
Follow-up for publication:
N = 574





Published trials N = 334
Fig. 1. Trials included in analysis. IRB, institutional review board.
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Key findings
 Ten percent of clinical drug trials (and 6% of the
randomized clinical drug trials) had a discrepancy
in the primary endpoint between the trial protocol
and the subsequent publication.
 Investigator-initiated trials were more likely to
have a protocol-publication discrepancy in the pri-
mary endpoint than industry-sponsored trials.
What this adds to what was known?
 The occurrence of protocol-publication discrep-
ancies in the primary endpoints was substantially
lower than what we expected based on the litera-
ture, especially among the randomized controlled
trials.
 Numerous discrepancies were identified in the
important reporting categories secondary end-
points, objectives, selection criteria, sample size,
subgroup or other additional analyses, and methods
used for data analysis.
What is the implication and what should change
now?
 More transparency is needed in the trajectory from
protocol until publication of clinical drug trials. A
practical solution is that the original trial protocol
is made available in the public domain at the same
time with the trial publication.
are not being published in the scientific literature [8].
Another type is selective publication, meaning that at least
some results are published, but with undisclosed discrep-
ancies between the trial protocol and the publication. The
first empirical study investigating the problem of selective
publication found that 62% of the trials had at least one pri-
mary endpoint that was discrepant between the trial proto-
col and the trial publication [9]. As the main conclusions
and recommendations of trials will be based on their pri-
mary outcome, this finding suggests that a substantial pro-
portion of clinical evidence is biased due to selective
publication. Other studies also showed an alarming amount
of selective publication regarding subgroup analyses, sam-
ple size calculations, and sponsorship acknowledgment
[10e13].
Although the existence of selective publication has been
convincingly established among clinical trials starting
15e20 years ago [9,10], its occurrence may have decreased
due to subsequent countermeasures. Governments, journals,
pharmaceutical companies, and research communities have
implemented requirements for trial registration and data
200 C.A. van den Bogert et al. / Journal ofsharing [14e20]. However, more recent evidence suggests
that only limited progress has been made [10]. Empirical
evidence is very limited on whether other aspects of trials
are transparently reported, such as the selection criteria,
sample size, subgroup or other additional analyses, and
the methods used for data analysis. Therefore, we studied
the occurrence of protocol-publication discrepancies, deter-
minants of discrepancies in primary endpoints, and the as-
sociation between discrepancies and the direction of trial
conclusions in a cohort of clinical drug trials.2. Methods
The design of the study has been published before [7]. In
short, we selected all the clinical drug trials that were re-
viewed by the Dutch-accredited institutional review boards
(IRBs) in 2007, and we followed these trials until publica-
tion as peer-reviewed article in the scientific literature. The
results of the study on nonpublication have been published
and showed that of the 574 trials in the cohort, 240 (42%)
remained unpublished [21]. For this follow-up study, we
included the 334 trials in the cohort of which we found at
least one publication by January 2016 in the scientific liter-
ature presenting results (Fig. 1). The data source was Toet-
singOnline, a database containing all clinical drug trials
submitted to accredited IRBs in the Netherlands, overseen
by the competent authority (the Central Committee on
Research Involving Human Subjects, CCMO). Hence, the
cohort consists of all clinical drug trials that were IRB re-
viewed in the Netherlands in 2007. The data sources for
the discrepancy assessment were the IRB files of the
CCMO including the original trial protocols and substantial
amendments (as required by law, these documents are sub-
mitted to both the IRB and the CCMO before start of the
trial or before implementation of the amendment). We
searched PubMed, Embase, and Google Scholar for publi-
cations of the trials in scientific journals. All publications
containing results of the trials were downloaded as full text.
The publication search was conducted in January and
February 2016. Thus, the minimal follow-up between
201C.A. van den Bogert et al. / Journal of Clinical Epidemiology 89 (2017) 199e208IRB approval and publication was 8 years (December 2007
to January 2016).
We identified discrepancies between the most recently
IRB-approved trial protocol (including IRB-approved sub-
stantial amendments) and the publications reporting results
of the trial at issue. If multiple publications of the same trial
were identified, all publications were included in the
assessment. Discrepancies were scored by comparing the
full text of the original protocol with the full texts of all
identified publications of the trial. Five categories of
protocol-publication discrepancies were measured: end-
points (the operationalization of events, symptoms, bio-
markers, etc., that were measured in the trial); trial
objectives (the general conceptual goals of the trial as
stated in the introduction of the protocols and the publica-
tions); selection criteria; sample size; and sponsor acknowl-
edgment. Two additional protocol-publication
discrepancies were only scored among the randomized
controlled trials (RCTs) in the cohort: discrepancies in
additional or subgroup analyses, and discrepancies in the
method used for the data analysis. The method used for
data analysis was defined as how the trial arms were
compared; for example, using the intention-to-treat, or the
per protocol approach for the analysis (and whether the
definition of the analysis population was similar in the pro-
tocol and in the publication). More details on the protocol-
publication categories are provided in the Web-only
Supplementary File, Table S1 at www.jclinepi.com.
Disclosure was the leading principle in scoring the dis-
crepancies. Aspects were only scored as being discrepant
if no reason for the discrepancy was provided in the pub-
lication, and we could not find another reason for the
discrepancy that was disclosed to the IRB (such as
approved substantial amendments). For example, if a pri-
mary endpoint was added in a publication compared with
the trial protocol, and the publication also explained this
addition, it was not considered discrepant. Similarly, a
post hoc subgroup analysis was only considered
discrepant if the post hoc nature of the subgroup analysis
was not stated in the publication. In addition, if the trial
was discontinued before the planned end of follow-up,
and this was reported in the publication, we did not score
the lower sample size as discrepancy. If multiple methods
for data analysis were described in the publication and on-
ly one was specified in the protocol, we only scored this
as being a discrepancy if the publication did not state
which method was specified in the protocol. In case that
multiple publications were found of one trial, omissions
were only scored as discrepancy if the omitted item was
not reported in any of the publications of the trial. Addi-
tions were scored as discrepancy if not labeled as post hoc
in all publications of the trial. If we found in one of the
publications an unexplained change compared with the
protocol, it was scored as a discrepancy, regardless
whether it was reported correctly in the other publications
of the trial.Trial characteristics were extracted from the
ToetsingOnline database, from the form that all trial appli-
cants filled out on a form at the time of submission of the
trial application for IRB review. This form is mandatory
and identical for all IRBs in the Netherlands. Other trial
characteristics were prospective registration in the interna-
tional registries of clinicaltrials.gov or ISRCTN, and
whether the trial was completed as planned or discontinued.
Other trial characteristics were the trial design (RCT supe-
riority, RCT noninferiority, or non-RCT/exploratory phar-
macology), and, only among the RCTs, the treatment
arms (parallel group or crossover). Associations between
these trial characteristics and protocol-publication discrep-
ancies in the primary endpoints were evaluated.
Among the subgroup of RCTs, we categorized the direc-
tion of conclusion of the trials as positive or negative, as
formulated in the publications. The direction of conclusion
was positive if the trial results supported the trial objectives
or hypotheses as stated in the protocol (eg, drug X is supe-
rior compared with placebo against disease Y). If the
conclusion section of the publication stated that the results
were negative, nonsignificant, or inconclusive, the direction
of conclusion was classified as negative. If more than one
publication was found of a trial, the first publication of
the completed trial that reported primary endpoints was
used to classify the direction of conclusion.
The protocol-publication discrepancies were described
using univariate analysis, stratified for RCTs and non-
RCTs. Randomized trials with exploratory objectives (eg,
phase-1 trials investigating pharmacology, safety, and toler-
ability) were included in the non-RCT stratum. For the dis-
crepancies in endpoints, objectives, and additional/
subgroup analyses, we merged the outcome variable by
calculating the sum total of primary endpoint discrepancies
and primary objective discrepancies, and the sum total of
discrepancies in additional or subgroup analyses.
We analyzed the association between the trial character-
istics that were considered as being potential determinants
of protocol-publication discrepancies. In addition to the
sponsor type, we analyzed the trial characteristics that were
significantly associated with nonpublication in the same
cohort [21]: phase, centers involved, prospective registra-
tion, and completion. Furthermore, in line with previous
studies [9,10], we also analyzed the association of the trial
design and the treatment arms with discrepancies in the pri-
mary endpoints. The protocol of our study [7] prescribed
the analysis of determinants for all protocol-publication
discrepancies separately. In this study, we focus on determi-
nants of the discrepancies in the primary endpoints, which
are most likely to influence the direction of conclusions of
the trials. Then, we analyzed the association between the
protocol-publication discrepancies and the direction of con-
clusions of the trials. To estimate the overall associations,
we used Pearson’s chi-square test and indicate the associa-
tions of P ! 0.01 and P ! 0.05. Furthermore, risk ratios
(RRs) and their 95% confidence interval (CIs) were










Pharmaceutical industry 208 62.3
Investigator [industry (co-)funded] 37 11.1
Investigator (no industry funding involved) 89 26.6
Phase
Phase 1 41 12.3
Phase 2 78 23.4
Phase 3 125 37.4
Phase 4 32 9.6
Other than phases 1e4a 58 17.4
Centers
Single center 113 33.8
Multicenter only in the Netherlands 29 8.7
Multicenter in the Netherlands and the EU 56 16.8
Multicenter in the Netherlands and outside the EU 136 40.7
Disease area
Oncology 75 22.5
Endocrine diseases 40 12.0
Neurological diseases (including analgesia
and anesthesia trials)
36 10.8
Infectious diseases (including vaccine trials) 32 9.6
Cardiovascular diseases 29 8.7
Respiratory diseases 25 7.5
Other disease areas 22 6.6
Musculoskeletal diseases 19 5.7
Mental and behavioral disorders 17 5.1
Hematological and immunological diseases 17 5.1
Digestive system diseases 12 3.6
Genitourinary system diseases 10 3.0
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sociations. If zero outcomes (or zero reciprocal outcomes)
were observed in categories with low numbers of trials,
the RR was not calculated as a zero cell count will strongly
bias the association toward statistical significance. The pro-
tocol of our study prescribed also multivariable logistic
regression analysis. However, because of the relatively
low number of discrepancies in the primary endpoints
(32), the precision of the regression coefficients would have
been low. Therefore, we decided to omit multivariable
analysis.
One investigator (C.A.v.d.B.) performed the discrepancy
scoring for all trials. A second investigator (P.C.S.) exam-
ined the reliability of the discrepancy scoring method.
The protocol prescribed an additional double-check of
10% of the cohort and subsequently a randomly selected
20 trials. After comparing the seven discrepancy categories
of the initial 35 trials selected for crosschecking (245 data
entries in total), three data entries were changed after dis-
cussion. These included one discrepancy in the selection
criteria, one discrepancy in the secondary endpoint, and
one discrepancy in the subgroup or additional analyses.
Thus, the interrater agreement was (1  (3/245)) 
100 5 99%, with no disagreements about discrepancies
in the primary endpoints. Based on the interrater agreement
of 99%, we concluded there was sufficient proof of reli-
ability of the scoring procedure and that the double-check
could be restricted to the randomly selected 35 trials
(10%). We included this protocol deviation in Table S2
(Web-Only Supplementary File at www.jclinepi.com).Prospective registrationb
Prospectively registered 161 48.2
Not (prospectively) registered 173 51.8
Completion
Completed as planned 300 89.8
Terminated early 34 10.2
Designc
RCT; superiority 169 50.6
RCT; noninferiority 35 10.5
Non-RCT and/or exploratory pharmacology trial 130 38.9
Treatment arms
Parallel group 226 67.7
Crossover 39 11.7
Single arm 69 20.7





Abbreviation: RCT, randomized controlled trial.
a Trials carriedoutusingmedicinalproducts inconnectionwithobjec-
tives other than those referred to in the phase definitions 1e4. Such trials
are not intended primarily to provide information about the product itself,
but a medicinal product is needed to address the objective of the trial.
b Prospective registration was defined as registration of the trial at
www.clinicaltrials.gov or www.isrctn.com, at latest 1 month after
institutional review board approval.
c Exploratory pharmacology trials that involved randomization but
no formal hypothesis testing (which is common in, eg, phase-1 random-
ized dose-escalation trials) were also excluded from the RCT subgroup.3. Results
Of the 334 trials that were published by January 2016
(Fig. 1), we identified 506 articles. Of 91% of these trials,
we found one or two articles (Table S3, Web-Only Supple-
mentary File at www.jclinepi.com). The characteristics of
the 334 trials are summarized in Table 1. The trials were
mostly industry sponsored (62.3%), phase 3 (37.4%), and/
or international multicenter (16.8% was also conducted in
other European (EU) countries, and 40.7% was also con-
ducted outside the EU). Oncology was the largest disease
area (22.5%), and most trials (51.8%) were not prospec-
tively registered at clinicaltrials.gov or ISRCTN. A small
proportion (10.2%) was discontinued before the planned
end of recruitment and/or follow-up. Sixty-one percent
were RCTs (50.6% superiority and 10.5% noninferiority),
and most trials had a parallel group design. Almost half
of the trials (47.9%) planned to include less than 100 par-
ticipants. Table 2 shows an overview of the protocol-
publication discrepancies that were measured in all 334 tri-
als. Omissions (N5 17; 5.1%) and changes (N5 14; 4.2%)
of the primary endpoint were more common than additions
(N 5 1; 0.3%). The most common discrepancies were in
secondary endpoints: 89 (43.6%) of the RCTs and 48
Table 2. Occurrence of protocol-publication discrepancies stratified for trial design
Discrepancy categories







Primary endpoint added in publication 1 (0.3) 0 (0.0) 1 (0.8)
Primary endpoint omitted in publication 17 (5.1) 3 (1.5) 14 (10.8)
Primary endpoints changed in publication 14 (4.2) 9 (4.4) 5 (3.8)
Sum total of discrepancies in primary endpointa 32 (9.6) 12 (5.9) 20 (15.4)
No discrepancy in primary endpoint, but discrepancy in secondary endpoint 137 (41.0) 89 (43.6) 48 (36.9)
No discrepancies in endpoints 163 (48.8) 102 (50.0) 61 (46.9)
No information in protocol and/or publication on endpoints 2 (0.6) 1 (0.5) 1 (0.8)
Discrepancies in objectives
Primary objective added in publication 2 (0.6) 2 (1.0) 0 (0.0)
Primary objective omitted in publication 12 (3.6) 2 (1.0) 10 (7.7)
Primary objective changed in publication 11 (3.3) 6 (2.9) 5 (3.8)
Sum total of discrepancies in primary objectivea 25 (7.5) 10 (4.9) 15 (11.5)
No discrepancy in primary objective, but discrepancy in secondary objective 64 (19.2) 47 (23.0) 17 (13.1)
No discrepancies in objectives 241 (72.2) 144 (70.6) 97 (74.6)
No information in protocol and/or publication on objectives 4 (1.2) 3 (1.5) 1 (0.8)
Discrepancies in selection criteria
Changed in publication 37 (11.1) 21 (10.3) 16 (12.3)
No discrepancies in selection criteria 295 (88.3) 183 (89.7) 112 (86.2)
No information in protocol and/or publication on selection criteria 2 (0.6) 0 (0.0) 2 (1.5)
Discrepancies in sample size
!80% of sample size as calculated in protocol included 32 (9.6) 10 (4.9) 22 (16.9)
O120% of sample size as calculated in protocol included 6 (1.8) 3 (1.5) 3 (2.3)
No discrepancies in selection criteria 296 (88.6) 191 (93.6) 105 (80.8)
No information in protocol and/or publication on sample size 0 (0.0) 0 (0.0) 0 (0.0)
Abbreviation: RCT, randomized controlled trial.
a Sum total of all discrepancies in primary endpoints or primary objectives.
b Randomized exploratory pharmacology trials were also included in the non-RCT stratum.
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mary endpoints but a discrepancy in the secondary end-
points. Discrepancies in the sample size were mainly due
to inclusion of !80% of the sample as calculated in the
protocol, which occurred in 10 (4.9%) of the RCTs and
in 22 (16.9%) of the non-RCTs. Three (1.5%) of the RCTs
and three (2.3%) of the non-RCTs included more than
120% of the sample size as calculated in the protocol.Table 3. Occurrence of protocol-publication discrepancies that were
only scored among the subgroup of randomized controlled trials
(RCTs)
Discrepancy categories N (%)
Number of trials assessed 204 (100)
Discrepancies in additional or subgroup analyses
Additional/subgroup analysis added in publication 25 (12.3)
Additional/subgroup analysis omitted in publication 62 (30.4)
Additional/subgroup analysis changed in publication 4 (2.0)
Sum total of discrepancies in additional or
subgroup analysisa
91 (44.6)
No discrepancies in additional or subgroup analysis 111 (54.4)
No information in protocol and/or publication on
subgroup analysis
2 (1.0)
Discrepancies in method used for data analysis
Method used for data analysis changed in the
publication
21 (10.3)
No discrepancies in method used for data analysis 147 (72.1)
No information in protocol and/or publication on
data analysis
36 (17.6)
a Sum total of all discrepancies in additional or subgroup analysis.Table 3 summarizes the discrepancy categories that were
only measured among the subgroup of 204 RCTs. Among
the 204 RCTs, 91 (44.6%) had a discrepancy in the sub-
group analysis. Furthermore, 21 (10.3%) of the RCTs had
a discrepancy in the methods used for data analysis. None
of the trials had a discrepancy in sponsorship acknowledg-
ments. Seventy-eight trials (23.3%) had no discrepancy at
all (Table S4, Web-Only Supplementary File at www.
jclinepi.com). In 36 (17.6%) of the RCT protocols and/or
publications, the methods used for data analysis were not
specified (Table 3). In 21 of the 204 RCTs (10.3%), it
was only missing in the protocol, in nine RCTs (4.4%) only
in the publications, and in six RCTs (2.9%) both in the pro-
tocol and in the publications. The information on the
methods used for data analysis was missing in 30
(55.6%) of the protocols and/or publications of the 54
investigator-initiated RCTs, and in 6 (4.0%) of the 150
industry-sponsored RCTs. The other discrepancy categories
were missing in the protocols and/or publications of zero to
four trials (0e1.5%).
Associations between trial characteristics and discrep-
ancies in the primary endpoints are shown in Table 4.
Investigator-initiated trials were associated with a higher
likelihood to have a discrepancy in the primary endpoints
compared with industry-sponsored trials, whether the indus-
try was involved as (one of) the funder(s) of the trial (RR 3.7,
95% CI 1.4e9.9 and RR 4.4, 95% CI 2.0e9.5, respectively).
Furthermore, trials not being classified as phases 1e4 had a
Table 4. Association between trial characteristics and protocol-publication discrepancies in primary endpoints
Trial characteristics Trials with primary endpoint discrepancy, N (%)c Chi-square RR (95% CI)
Sponsor 17.82a
Pharmaceutical industry (N 5 208) 9 (4.3) Ref
Investigator [industry (co-)funded; N 5 37] 6 (16.2) 3.7 (1.4e9.9)
Investigator (no industry funding involved; N 5 89) 17 (19.1) 4.4 (2.0e9.5)
Phase 17.04a
Phase 1 (N 5 41) 2 (4.9) Ref
Phase 2 (N 5 78) 6 (7.7) 1.6 (0.3e7.5)
Phase 3 (N 5 125) 6 (4.8) 1.0 (0.2e4.7)
Phase 4 (N 5 32) 5 (15.6) 3.2 (0.7e15.4)
Other than phases 1e4d (N 5 58) 13 (22.4) 4.6 (1.1e19.3)
Centers 15.42a
Single center (N 5 113) 19 (16.8) Ref
Multicenter only in the Netherlands (N 5 29) 5 (17.2) 1.0 (0.4e2.5)
Multicenter in the Netherlands and the EU (N 5 56) 3 (5.4) 0.3 (0.1e1.0)
Multicenter in the Netherlands and outside the EU (N 5 136) 5 (3.7) 0.2 (0.1e0.6)
Prospective registratione 9.83a
Prospectively registered (N 5 161) 7 (4.3) Ref
Not (prospectively) registered (N 5 173) 25 (14.5) 3.3 (1.5e7.5)
Completion 0.03
Completed as planned (N 5 300) 29 (9.7) Ref
Discontinued before planned end (N 5 34) 3 (8.8) 0.9 (0.3e2.8)
Designf 8.72b
RCT; superiority (N 5 169) 11 (6.5) Ref
RCT; noninferiority (N 5 35) 1 (2.9) 0.4 (0.1e3.3)
Non-RCT and/or exploratory pharmacology trial (N 5 130) 20 (15.4) 2.4 (1.2e4.8)
Subgroup of RCTs 204 (100)
Discrepancies in primary endpointsc 12 (5.9)
Treatment arms 4.64b
Parallel group (N 5 187) 9 (4.8) Ref
Crossover (N 5 17) 3 (17.6) 3.7 (1.1e12.3)
Abbreviations: RR, risk ratio; CI, confidence interval; RCT, randomized controlled trial.
a P-value ! 0.01 (based on Pearson’s chi-square).
b P-value between 0.01 and 0.05 (based on Pearson’s chi-square).
c The sum total of discrepancies in primary endpoints (N 5 32; see Table 2), or for the subgroup of RCTs (N 5 12).
d Trials carried out using medicinal products in connection with objectives other than those referred to in the phase definitions 1e4. Such trials
are not intended primarily to provide information about the product itself, but a medicinal product is needed to address the objective of the trial
[31].
e Prospective registration was defined as registration of the trial at the international public registers www.clinicaltrials.gov or www.isrctn.com,
at latest 1 month after institutional review board approval.
f Exploratory pharmacology trials that involved randomization but no formal hypothesis testing (which is common in, eg, phase-1 randomized
dose-escalation trials) were also excluded from the RCT subgroup.
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compared with phase-1 trials (RR 4.6, 95% CI 1.1e19.3).
Multicenter trials also conducted outside the EU had a lower
likelihood of having a discrepancy in the primary endpoints
compared with single-center trials (RR 0.2, 95% CI
0.1e0.6). Trials that were not prospectively registered in
clinicaltrials.gov or the ISRCTN registry were more likely
to have a discrepancy in the primary endpoints compared
with trials that were prospectively registered (RR 3.3, 95%
CI 1.5e7.5). Compared with superiority RCTs, non-RCTs
had a higher likelihood to have a discrepancy in the primary
endpoint (RR 2.4, 95%CI 1.2e4.8). This associationwas not
observed when comparing superiority RCTs with noninfer-
iority RCTs (RR 0.4, 95% CI 0.1e3.3). Finally, crossover
RCTs had a higher likelihood of discrepancies in the primary
endpoint compared with parallel group RCTs (RR 3.7, 95%
CI 1.1e12.3).Table 5 shows the association between the protocol-
publication discrepancies and a positive direction of the
trial conclusions. In none of the discrepancy categories,
having a protocol-publication discrepancy in that category
was associated with a positive direction of trial conclusions.4. Discussion
We found that 9.6% of all clinical drug trials, and 5.9%
of the RCTs, in our study had a protocol-publication
discrepancy in the primary endpoints. This is a substan-
tially lower proportion than reported by the two previous
studies investigating this issue. Chan et al. found discrep-
ancies in primary endpoints among 62% of RCTs [9]. Be-
rendt et al. conducted a study among academic
(investigator-initiated) trials and found discrepancies in
primary endpoints in 38% and 43% in non-RCTs and
Table 5. Association between protocol-publication discrepancies of the subgroup of randomized controlled trials (RCTs) and the direction of
conclusion
Discrepancy categories
RCTs with positive direction of
conclusion, N (%) Chi-squarea RR (95% CI)
Endpoints 4.29
No discrepancies (N 5 102) 75 (73.5) Ref
Primary endpoint added in publication (N 5 0) d d
Primary endpoint omitted in publication (N 5 3) 2 (66.7) 0.9 (0.4e2.0)
Primary endpoint changed in publication (N 5 9) 4 (44.4) 0.6 (0.3e1.3)
Secondary endpoint omitted/added/changed in publication (N 5 89) 59 (66.3) 0.9 (0.7e1.1)
No information in protocol (N 5 1) 1 (100) db
Objectives 8.37
No discrepancies (N 5 144) 105 (72.9) Ref
Primary objective added in publication (N 5 2) 2 (100) db
Primary objective omitted in publication (N 5 2) 0 (0) db
Primary objective changed in publication (N 5 6) 4 (66.7) 0.9 (0.5e1.6)
Secondary objective omitted/added/changed in publication (N 5 47) 28 (59.6) 0.8 (0.6e1.1)
No information in protocol (N 5 3) 2 (66.7) 0.9 (0.4e2.0)
Selection criteria 0.06
No discrepancies (N 5 183) 126 (68.9) Ref
Changed in publication (N 5 21) 15 (71.4) 1.0 (0.8e1.4)
No information in protocol (N 5 0) d d
Sample size 3.26
No discrepancies (N 5 191) 133 (69.6) Ref
!80% of sample size as calculated in protocol included (N 5 10) 6 (60.0) 0.9 (0.5e1.4)
O120% of sample size as calculated in protocol included (N 5 3) 2 (66.7) 1.0 (0.4e2.1)
No information in protocol (N 5 0) d d
Additional/subgroup analyses 3.06
No discrepancies (N 5 111) 76 (68.5) Ref
Additional/subgroup analysis added in publication (N 5 25) 18 (72.0) 1.1 (0.8e1.4)
Additional/subgroup analysis omitted in publication (N 5 62) 41 (66.1) 1.0 (0.8e1.2)
Additional/subgroup analysis changed in publication (N 5 4) 4 (100) db
No information in protocol (N 5 2) 2 (100) db
Methods used for data analysis 1.85
No discrepancies (N 5 147) 101 (68.7) Ref
Changed in publication (N 5 21) 17 (81.0) 1.2 (0.9e1.5)
No information in protocol (N 5 36) 23 (63.9) 0.9 (0.7e1.2)
Abbreviations: RR, risk ratio; CI, confidence interval; RCT, randomized controlled trial.
a None of the Pearson’s chi-square tests indicated a statistically significant association (P! 0.05) between protocol-publication discrepancies
and a positive direction of trial conclusions.
b In case 100%, or 0%, of the RCTs within a category with a low number of trials had a positive direction of conclusion, the risk ratio was not
calculated because a zero cell count would bias the estimation of the 95% CI toward statistical significance.
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demic trials in our cohort, discrepancies in primary end-
points were found in 10 of 54 RCTs (19%), and in 13
of 72 non-RCTs (18%). This finding suggests that also
the reporting of academic trials has been improved.
Furthermore, both in RCTs and in non-RCTs, protocol-
publication discrepancies were substantial in secondary
endpoints: 89 (44%) and 48 (37%), respectively. These
proportions were also considerably lower than those of
the recent COMP are initiative [22], which reported dis-
crepancies in endpoints among 87% of the trials (not
differentiating between primary and secondary endpoints).
Discrepancies in primary objectives were found in 7%
(N 5 25) of the trials, and in 5% (N 5 10) of the RCT
subgroup. This is also lower than the previous study that
investigated this discrepancy [10]. In line with secondary
endpoints, discrepancies in secondary objectives occurredin 19% (N 5 64) of the trials and in 23% (N 5 47) of
the RCTs. We found a discrepancy in selection criteria
in 11% (N 5 37) of the trials, and in 10% (N 5 21) of
the RCTs. To our knowledge, our study is the first to
investigate this. Discrepancies in the sample size were also
found in 11% (N 5 38) of the trials, and in 6% (N 5 13)
of the RCTs. This finding is considerable lower than re-
ported in a previous study, which found discrepancies in
sample size calculations in 53% of the RCTs [23].
Among 91 (45%) of the 204 RCTs, we also found dis-
crepancies in subgroup or other additional analyses. In this
discrepancy category, omissions of subgroup or additional
analysis that were planned in the protocol were most com-
mon. Omissions of planned subgroup analyses are, to our
knowledge, not investigated in previous studies. The 25
RCTs (12%) that added an unplanned subgroup analysis
and did not label it as being post hoc are lower than a
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the RCTs changed the method used for data analysis. This
is also considerably lower compared with findings by a pre-
vious study [23].
The reason for the lower occurrence of discrepancies
compared with the three previous cohort studies [9e11]
may be that more clinical investigators and journals are
aware of the importance of complete and accurate reporting
of all protocol aspects. In 2007, the Standard Protocol
Items: Recommendations for Interventional Trials
(SPIRIT) Statement initiative was launched. Furthermore,
the CONsolidated Standards of Reporting Trials (CON-
SORT) statement was updated in 2010. The broad attention
to and implementation of these initiatives by the major
medical journals might have contributed to better reporting
[19,24e29]. Another reason could be related to the infor-
mation that was available to explain the observed differ-
ences between protocols and publications. If a potential
discrepancy was identified, we exhaustively searched sub-
stantial amendments and follow-up publications to explain
the difference. If these explanations were available, for
example, in online supplementary files or in publications
other than the main results publication, we did not consider
it as being a discrepancy. Hence, it might have made a dif-
ference whether the research team was determined to find
as many discrepancies as possible, or find as many explana-
tions for potential discrepancies as possible. Another reason
for the difference with two of the previous cohorts is that
we included all available publications in the assessment,
whereas these studies only included one publication for
each trial protocol [9,11,23]. The third previous cohort
study [10] had only a follow-up from IRB approval until
publication of 5 years, which is likely too short to identify
all relevant (additional) publications [30].
We replicated the previous findings that non-RCTs/
exploratory trials have more discrepancies than RCTs
[10], and that, among the RCTs, trials with a crossover
treatment arm have more discrepancies compared with par-
allel group treatment arms [9]. Furthermore, the analysis of
trial characteristics suggests that discrepancies in primary
endpoints mainly occur in small, local, investigator-
initiated trials not in the context of drug product develop-
ment (other than phases 1e4 [31]), that also were less
likely to be prospectively registered. These characteristics
often coincide. A reason for this may be that such trials
are more flexible in the choice of endpoints, as the protocol
and subsequent publications will not be reviewed by the
drug marketing authorization authorities (who request stan-
dardized endpoints for a given disease area [32]). These an-
alyses elucidate trial types that have remained outside the
reach of the past initiatives and countermeasures against se-
lective reporting.
No discrepancy categories were significantly associated
with a positive direction of conclusion of the RCT subgroup.
This suggests that the observed discrepancies have not been
introduced in the publications to change the overall directionof conclusion of the trials. However, this was only assessed
using a binary classification of direction of conclusion, leav-
ing no room for nuances. In particular, the discrepancies in
primary and secondary endpoints may still have led to a
‘‘more positive,’’ or ‘‘less negative’’ conclusion, thereby
introducing reporting bias [22,33]. If investigators measure
several endpoints and can decide afterward which to report,
the likelihood is high that those endpoints are reported that fit
expectations or desires [34]. If objectives are discrepant, the
publication may fail to provide an accurate description of the
original rationale and research question of the trial. This can
be relevant for the interpretation of results. Discrepancies in
the sample size can bias the interpretation of results, as the
likelihood of erroneous chance findings is high if the sample
size is too small [35]. Discrepancies in the methods used for
data analysis can also be a way to spin the interpretation of
results toward the preferred conclusion, for example, by
excluding or including outliers or cases with partially
missing data entries. Not reporting planned subgroup ana-
lyses occur likely because of the absence of effect, and un-
planned subgroup analyses were probably added post hoc
because therewas an (unexpected) effect. Although the latter
can serendipitously lead to important discoveries, their
exploratory nature should be clearly acknowledged when
they are reported [2,36]. Furthermore, protocol-publication
discrepancies in the selection criteria can affect the ethical
justification to include certain participants in the trial. For
example, a protocol in the cohort prescribed inclusion of on-
ly patients with a given tumor characterized as grade 4 (the
tumor grade indicating the most severe grade of illness).
The publication reported inclusion of patients with tumor
grades 3e4. However, as the protocol stated only the inclu-
sion of grade-4 tumors, the IRB had approved the trial to be
conducted specifically in the population with grade 4. The
IRB had not considered grade-3 tumors in their evaluation,
and investigators were therefore not permitted to include
these patients. In addition, including more participants than
needed according to the protocol can also be unethical. The
research question could then have been answered at the cost
of a smaller number of participants being exposed to risks
and burdens of the trial [37].
In our cohort, the magnitude of nonpublication likely ex-
ceeded the magnitude of selective publication in terms of
causing research waste and publication bias. Of the 574
drug trials initially followed until publication, 42% re-
mained unpublished [21], and of the published trials, 32
(10%) had discrepancies in the primary endpoints. Never-
theless, the identified discrepancies could still have intro-
duced spin and bias in the trial publications [38]. Trial
publications should therefore become more transparent
and provide a clear track record of the process of a clinical
trial, from the initial research protocol until the publications
presenting the results [39]. Some journals published the
trial protocol as well as protocol amendments as online sup-
plement, but this was rather an exception than common
practice. To further facilitate independent interpretation of
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part of the protocol changed, when and why, and to which
extent this may have influenced the conclusions [40]. This
discrepancy checklist could then also be included in the
assessment of bias (such as outcome reporting bias), which
should be done when the trials are included in systematic
reviews [4,41,42]. The finding that 20% of the RCTs
missed information in the protocol and/or the publication
about the methods used for data analysis attends IRBs
and journals to always request this important information
[20,24]. This attention is especially needed for the
investigator-initiated RCTs.
A strength of our study is that the selection of protocols
was not limited to those that are publicly available, thereby
avoiding selection bias. We had access to all clinical drug tri-
als that were submitted to an IRB in 2007. Furthermore, we
did not limit our discrepancy assessment to the endpoints but
assessed seven essential trial aspects that should be consis-
tent between trial protocol and subsequent publications. As
we included trials across all medical specialties, and 57%
of the trials were multicenter international trials, our findings
can be considered as being generalizable across geograph-
ical and medical areas. Although a higher sample size would
have enabled a more precise conclusion, the number of 334
trials included in our cohort is higher than most previous
studies, with the exception of the study by Kasenda et al.
[9e11,23]. A limitation of our study was that we might have
missed some documents explaining the discrepancies that
were not included in the CCMO-archive. However, this
missing information would then be incidental and therefore
unlikely systematic or differential. And, if substantial
amendments were missing in the archives, a record of these
as well as nonsubstantial amendments should nevertheless
have been provided in the publication, thus discrepancies
scored as a result from these missing documents can be justi-
fied. Another limitation is that we might have missed some
publications that were published after the follow-up period
or were missed in the publication search. Finally, a limitation
was the low number of cases in some trial characteristic cat-
egories (eg, investigator-initiated trials), which limited the
precision of the risk estimates. We could, therefore, not
perform multivariable analysis. Conclusions regarding the
associations between trial characteristics and discrepancies
should be interpreted with caution.
To conclude, protocol-publication discrepancies in clin-
ical drug trials were not unusual in primary endpoints, but
common in secondary endpoints, secondary objectives, and
subgroup or other additional analyses. Despite the improve-
ment compared with previous studies, the occurrence of
discrepancies was still substantial, indicating that selective
publication remains a problem in clinical research.
Investigator-initiated, not prospectively registered and non-
randomized trials were determinants of discrepancies in the
primary endpoint. Full transparency of the process of clin-
ical trial protocols to publications can eliminate these op-
portunities for selective reporting. Practically, this couldmean that the original trial protocol and substantial amend-
ments are made publically available at the moment of pub-
lication of the results of the trial. That is likely the essential
way forward in pursuing ethically sound and scientifically
valid clinical research.Acknowledgments
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